Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability (Q34088274)

30 July 2017

Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability (English)

1 reference

30 July 2017

1 reference

Kenichi Kimoto

1

1 reference

PubMed ID

22132316

30 July 2017

Toshiaki Kubota

series ordinal

2

1 reference

30 July 2017

3 November 2011

1 reference

30 July 2017

Journal of Ophthalmology

1 reference

30 July 2017

2012

1 reference

30 July 2017

852183

1 reference

Creative Commons Attribution 3.0 Unported

30 July 2017

start time

1 January 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Repeated intravitreal bevacizumab (Avastin(®)) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Clinical factors related to recurrence of anterior segment neovascularization after treatment including intravitreal bevacizumab

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Endogenous VEGF is required for visual function: evidence for a survival role on müller cells and photoreceptors

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Ranibizumab for neovascular age-related macular degeneration

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Vascular endothelial growth factor controls neuronal migration and cooperates with Sema3A to pattern distinct compartments of the facial nerve

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Vascular endothelial growth factor: basic science and clinical progress

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Neovascular tissue in the intertrabecular spaces in eyes with neovascular glaucoma.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Tumor angiogenesis: therapeutic implications

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Neovascularization of the iris (rubeosis iridis)

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration

28 July 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F852183

A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F852183

Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F852183

Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F852183

Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F852183

Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F852183

Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F852183

Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F852183

Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F852183

Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F852183

Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F852183

Combined intravitreal bevacizumab and trabeculectomy with mitomycin C versus trabeculectomy with mitomycin C alone for neovascular glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F852183

Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F852183

Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F852183

The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F852183

Supplemental oxygen improves diabetic macular edema: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F852183

Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F852183

Angiographic changes in iris and iridocorneal angle neovascularization after intravitreal bevacizumab injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F852183

Trabecular meshwork in neovascular glaucoma eyes after the intravitreal injection of bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F852183

Histopathology of neovascular tissue from eyes with proliferative diabetic retinopathy after intravitreal bevacizumab injection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F852183

Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F852183

The role of vascular endothelial growth factor in ocular health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F852183

Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F852183

Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F852183

Histology of fibrovascular membranes of proliferative diabetic retinopathy after intravitreal injection of bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F852183

Outcome of eyes developing retinal detachment during the Early Treatment for Retinopathy of Prematurity Study (ETROP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F852183

Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F852183

Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F852183

Fluorescein angiography of recurrent retinopathy of prematurity after initial intravitreous bevacizumab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F852183

Vitrectomy after intravitreal bevacizumab (Avastin) for retinal detachment in retinopathy of prematurity

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F852183

Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F852183

Diabetic retinopathy: a growing concern in an aging population.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Intravitreal bevacizumab in a patient with neovascular glaucoma.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Quantitative assessment of the integrity of the blood-retinal barrier in mice

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Serum proteins and aqueous outflow resistance in bovine eyes.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216356

Ten-year incidence of visual loss in a diabetic population

28 October 2018

1 reference

12 December 2020

The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas

1 reference

12 December 2020

Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial

1 reference

12 December 2020

Endothelial fenestrae in proliferative diabetic retinopathy

1 reference

12 December 2020

Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2

1 reference

12 December 2020

Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab

1 reference

12 December 2020

Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study

1 reference

12 December 2020

Beneficial effects of preoperative intravitreal bevacizumab on trabeculectomy outcomes in neovascular glaucoma

1 reference

12 December 2020

Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma

1 reference

12 December 2020

Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease

1 reference

12 December 2020

Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy

1 reference

12 December 2020

Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates

1 reference

12 December 2020

Immunohistochemical localisation of intravitreally injected bevacizumab in the anterior chamber angle, iris and ciliary body of the primate eye

1 reference

12 December 2020

Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial

1 reference

12 December 2020

Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1

1 reference

12 December 2020

Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system

1 reference

12 December 2020

Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients

1 reference

12 December 2020

Avastin use in high risk corneal transplantation

1 reference

12 December 2020

Partial retinal detachment at 3 months after threshold retinopathy of prematurity. Long-term structural and functional outcome. Multicenter Trial of Cryotherapy for Retinopathy of Prematurity Cooperative Group

1 reference

12 December 2020

Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy

1 reference

12 December 2020

Vascular endothelial growth factor upregulation in human central retinal vein occlusion

1 reference

12 December 2020

Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES)

1 reference

12 December 2020

Regression of neovascular iris vessels by intravitreal injection of bevacizumab

1 reference

12 December 2020

Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study

1 reference

12 December 2020

Intracameral bevacizumab for iris rubeosis

1 reference

12 December 2020

Preoperative intravitreal bevacizumab use as an adjuvant to diabetic vitrectomy: histopathologic findings and clinical implications

1 reference

12 December 2020

The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing

1 reference

12 December 2020

Rapid regression of disc neovascularization in a patient with proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab

1 reference

12 December 2020

Identifiers

DOI

10.1155/2012/852183

1 reference

30 July 2017

1 reference

30 July 2017

1 reference

PubMed ID

22132316